From 6–8 October 2026, Alzheimer Europe participated in the 13th Lausanne Workshop, held in Switzerland. The annual meeting brought together representatives from research, industry, government and civil society to discuss progress in Alzheimer’s disease research and the challenges of translating scientific advances into clinical practice. Discussions covered new treatments, blood-based biomarkers, digital cognitive assessments, prevention and the economic implications of Alzheimer’s disease. A recurring theme was the need for healthcare systems and policies to keep pace with scientific innovation, while ensuring equitable access to diagnosis, treatment and care.
Angela Bradshaw, Deputy Executive Director of Alzheimer Europe, contributed to a panel discussion entitled “Policy at the Breaking Point: Keeping Pace with Alzheimer’s Innovation”, moderated by Chris Lynch of Alzheimer’s Disease International, with panelists Katrin Seeher (WHO Europe) and Hilal Lashuel (Weill Cornell Medicine Quatar). The session explored policy challenges associated with advances in Alzheimer’s diagnosis and treatment, including healthcare readiness and equitable access.
Wiesje van der Flier, CEO of Alzheimer Nederland and Board member of Alzheimer Europe, also contributed to the Workshop, participating in a panel entitled “Blood-Based Biomarkers: Redefining the Path to Diagnosis”. The session examined the potential of blood-based biomarkers to improve diagnostic pathways and support earlier detection of Alzheimer’s disease.
The Workshop also saw the publication of a Global Communiqué calling for greater political commitment to Alzheimer’s prevention.
Read the Lausanne XIII summary report
